Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2019 Dec 27;9:20098. doi: 10.1038/s41598-019-56480-1

Divergent expression patterns of pituitary gonadotropin subunit and GnRH receptor genes to continuous GnRH in vitro and in vivo

Marija M Janjic 1,2,#, Rafael M Prévide 1,#, Patrick A Fletcher 3, Arthur Sherman 3, Kosara Smiljanic 1, Daniel Abebe 1, Ivana Bjelobaba 1,2, Stanko S Stojilkovic 1,✉
PMCID: PMC6934515  PMID: 31882740

Abstract

Continuous, as opposed to pulsatile, delivery of hypothalamic gonadotropin-releasing hormone (GnRH) leads to a marked decrease in secretion of pituitary gonadotropins LH and FSH and impairment of reproductive function. Here we studied the expression profile of gonadotropin subunit and GnRH receptor genes in rat pituitary in vitro and in vivo to clarify their expression profiles in the absence and continuous presence of GnRH. Culturing of pituitary cells in GnRH-free conditions downregulated Fshb, Cga, and Gnrhr expression, whereas continuous treatment with GnRH agonists upregulated Cga expression progressively and Gnrhr and Fshb expression transiently, accompanied by a prolonged blockade of Fshb but not Gnrhr expression. In contrast, Lhb expression was relatively insensitive to loss of endogenous GnRH and continuous treatment with GnRH, probably reflecting the status of Egr1 and Nr5a1 expression. Similar patterns of responses were observed in vivo after administration of a GnRH agonist. However, continuous treatment with GnRH stimulated LH secretion in vitro and in vivo, leading to decrease in LH cell content despite high basal Lhb expression. These data suggest that blockade of Fshb expression and depletion of the LH secretory pool are two major factors accounting for weakening of the gonadotroph secretory function during continuous GnRH treatment.

Subject terms: Peptide hormones, Pituitary gland

Introduction

Mammalian reproduction depends on proper synthesis and release of two gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), by specialized endocrine cells of the anterior pituitary named gonadotrophs1. These hormones are dimeric glycoproteins composed of a common glycoprotein hormone, α polypeptide (Cga) and unique β subunits (Lhb and Fshb) that confer biological specificity2. The secretion of gonadotropins is tightly regulated by hypothalamic and intrapituitary factors. Among them, the most important is gonadotropin-releasing hormone (GnRH), which is released in a pulsatile manner by a small set of neurons within the preoptic area and mediobasal hypothalamus3. Upon reaching the anterior pituitary, GnRH binds to its receptor expressed in gonadotrophs and signals through a Gq/11-dependent cascade of intracellular pathways that culminates in periodic gonadotropin secretion4.

The pulsatile pattern of GnRH release is critical for proper gonadotropin synthesis and release. This was initially established in rhesus monkeys with hypothalamic lesions, which abolish endogenous GnRH secretion, where blood levels of LH and FSH were undetectable. Reintroduction of pulsatile GnRH administration rescued gonadotropin secretion, and subsequent continuous GnRH infusion lead to marked decrease in blood LH and FSH levels5. Subsequent experiments by the same group also revealed that LH levels were maximally stimulated at a higher GnRH pulse frequency than FSH6. The requirement of pulsatile GnRH release for the proper reproductive function was subsequently confirmed in other mammalian species3. Several physiological responses and pathological conditions that cause reproductive failure in humans are also associated with dysregulation of pulsatile GnRH release, including functional hypothalamic amenorrhea, hyperprolactinemia, polycystic ovary syndrome, and hypogonadotropic hypogonadism7–10. Continuous GnRH receptor agonist treatments are also clinically relevant, for example, for prevention of ovarian hyperstimulation syndrome during assisted reproduction11,12, for ovarian protection during chemotherapy13, and for treatments of precocious puberty14 and polycystic ovary syndrome15.

In general, the gonadotroph subunit genes, Cga, Fshb, and Lhb, exhibit basal and regulated expression, and it has been shown that they are stimulated by pulsatile GnRH application1. For example, in vivo pulsatile application of GnRH in male rats16, and in vitro pulsatile delivery of GnRH to cultured pituitary cells from male rats17 and pituitary fragments from female rats18 increased the transcription of gonadotropin subunit genes. In parallel to serum gonadotropin levels, Fshb was found to be preferentially transcribed at lower GnRH pulse frequencies, whereas Lhb was suggested to be preferentially transcribed at higher pulse frequencies administrated to male rats16,19 and to cultured pituitary cells from male rats17. Thus, the transcriptional regulation of gonadotropin subunit genes by pulsatile GnRH could be a critical point that determines gonadotropin biosynthesis and secretion, suggesting the hypothesis that continuous GnRH treatment may cause downregulation of gonadotropin subunit gene expression, leading to downregulation of gonadotropin release.

However, the mechanism of downregulation of gonadotropin release by continuous GnRH treatment has not been clarified. Shupnik’s group observed stimulation of Fshb and Lhb transcription in static cultures of pituitary fragments from female rats during the first 6 h continuous application of GnRH, but they did not detect inhibition of basal expression of these genes18. The same group also reported lack of changes in Cga, Lhb, and Fshb transcription compared to controls after continuous in vivo application of GnRH for 4 h in male rats16. In perifused rat pituitary cells, Fshb expression was stimulated by pulsatile delivery of GnRH for 12 h, but inhibited by continuous GnRH application, whereas Lhb mRNA levels were unresponsive to either mode of GnRH application20. The intrapituitary Fshb expression and circulating FSH levels are often highly correlated, and FSH was suggested to be secreted by constitutive exocytosis21 (and references within). In contrast, LH is secreted by regulated exocytosis22, i.e. GnRH receptor controls Lhb expression, LH release, or both.

Here, we evaluated the time course of gonadotropin subunit gene expression in static cultures of rat anterior pituitary during continuous GnRH treatment. We also studied the expression of transcription factor genes Egr1, Nr5a1, and Pitx1, which are critically important for control of expression of Lhb23–25. In addition, we characterized the acute and long-term effects of cell dispersion and primary culture in the absence of GnRH for these genes and commonly used reference genes before examining the effect of continuous GnRH treatment. Furthermore, we studied the relationship between Lhb expression, LH cell content, and LH release in vitro during continuous GnRH treatment. Finally, we evaluated effects of in vivo injection of a GnRH receptor agonist and antagonist on expression of gonadotropin subunit genes and LH serum and pituitary content. The expression of Gnrhr and Dmp1, which we characterized recently26,27, were used as internal controls in both in vitro and in vivo experiments. Our results indicate that continuous GnRH application progressively stimulates Cga expression, blocks Fshb expression after a transient stimulation, and causes a profound effect on LH secretion without major effects on Lhb expression.

Methods

Animals and experimental procedures

In vitro experiments were performed with anterior pituitary cells derived from 8-12-week-old Sprague Dawley rats obtained from Taconic Farms (Germantown, NY). Animals were euthanized via asphyxiation with CO2. After decapitation anterior pituitary glands were removed and cells were mechanically dispersed after trypsin and EDTA treatments as previously described28. If not otherwise specified, experiments were performed with cells from females. Cells were seeded on poly-D-lysine coated 24-well plates and initially cultured in medium 199 containing Earle’s salts, sodium bicarbonate, penicillin (100 units per ml), streptomycin (100 µg per ml) and 10% heat-inactivated horse serum (HS) (Life Technologies, Grand Island, NY). After overnight incubation, cells were bathed in medium 199 Earle’s salt solution containing 0.1% BSA in the presence of GnRH or D-Ala6-GnRH (D-Ala6) (Sigma, St Louis, MO). At the end of the experiments, incubation medium was collected, centrifuged at 3000 rpm to remove cell debris, and the supernatant was collected and stored at −80 °C for determining LH concentration. Attached cells were scraped for RNA extraction or LH measurement. For in vivo experiments, 4-week old animals were injected once intraperitoneally with a GnRH receptor agonist, buserelin acetate (5 µg/0.4 ml/per animal) from Sigma (St. Louis, MO), a GnRH receptor antagonist, cetrorelix acetate (100 µg/0.4 ml/per animal) from Tocris (Minneapolis, MN), or vehicle (0.4 ml/per animal). Euthanasia was performed 0.5, 1, 1.5, 2, 3, 6, or 9 hours after intraperitoneal injections. After decapitation, blood was collected, and serum was separated and stored at −80 °C for LH concentration measurement. Whole anterior pituitaries were individually collected in RNA stabilization solution (Thermo Fisher Scientific, Waltham, MA) for RNA extraction or individually frozen without solution for measurement of LH tissue content (as described below). All experimental procedures were in accordance with the National Institutes of Health Policy Manual 3040-2: Animal Care and Use in the Intramural Program and were approved by the National Institute of Child Health and Human Development, Animal Care and Use Committee (Animal Protocol 16-041).

LH measurements

Concentration of LH in samples was determined using an LH Rodent Elisa Kit (Endocrine Technologies, Newark, CA), according to the manufacturer instructions. Samples (blood serum, incubation medium, pituitary tissue content and cell content) were diluted appropriately if needed. For LH tissue content measurements, pituitaries were homogenized in 20 mM sodium carbonate. The homogenate was centrifuged (3000 rpm) and supernatant was transferred to a new vial. Protein concentration was then measured by the PierceTM BCA assay (Thermo Fisher Scientific, Waltham, MA) and samples were equalized to contain the same total protein concentration prior to Elisa LH measurement.

qRT-PCR analysis

Total RNA was extracted from individual anterior pituitary glands and primary cultures of anterior pituitary cells using an RNeasy Plus Mini Kit (Qiagen, Valencia, CA). RNA was reverse transcribed with a Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Sciences, IN). An analysis of relative gene expression was performed using qRT-PCR and the comparative Ct method. For this, the LightCycler TaqMan Master Mix and the Lightcycler 2.0 Real-time PCR system (Roche Applied Science, Indianapolis, IN), or Power SYBR Green Master Mix and Quant Studio 3 system (Thermo Fisher Scientific, Waltham, MA) were used. Applied Biosystems predesigned TaqMan Gene Expression Assays were used: Cga: Rn01440184_m1, Lhb: Rn00563443_g1, Fshb: Rn01484594_m1, Gnrhr: Rn00578981_m1, Dmp1: Rn01450122_m1, and Gapdh: Rn01462662_g1, Rpl19: Rn00821265_g1, Rps18: Rn01428913_gH, Egr1: Rn00561138_m1, Nr5a1: Rn00584298_m1, and Pitx1: Rn 00586187_m1. The primer sequences (Integrated DNA Technologies, Skokie, IL) used in SYBR Green quantitative real-time PCR are listed in Table S1.

To compare the relative expression levels of the transcripts, the levels were normalized against a reference gene, i.e. an internal reaction control that had sequences different than the target29. Several reference genes have been suggested for qRT-PCR analysis in anterior pituitary based on previous work with normal and pathological pituitary tissues and dispersed pituitary cells from different laboratories30–34. Figs. S1 and S2 show the expression patterns of these genes obtained from our single-cell RNA sequencing analysis of freshly dispersed male and female rat anterior pituitary cells35. Out of 19 genes studied, only eight genes were expressed in over 90% of anterior pituitary cells: Rpl19, Rpl32, Rps18, Gapdh, Rpl4, Rplp0, B2m, and Actb. Among them, only five genes exhibited comparable expression levels in all subpopulations of anterior pituitary cells: Rpl19, Rpl32, Rps18, Gapdh, and Rpl4. For further testing, we selected Rpl19, Rps18, and Gapdh because their Ct values, estimated in pituitary tissue, were comparable to the Lhb Ct values: Rpl19 = 21.46 ± 0.07; Rps18 = 22.37 ± 0.06; Gapdh = 23.85 ± 0.07; and Lhb = 22.15 ± 0.11.

To further study the validity of these candidate genes for qRT-PCR analysis of in vitro experiments, we examined the time-courses of their expression patterns after cell dispersion. We observed a decay in Ct values for all three candidate genes during the first 17 h of incubation, independent of the serum used for culturing (HS, BSA, or fetal bovine serum), suggesting that expression of these housekeeping genes increased after cell dispersion. To illustrate those changes, we used the Ct value at the beginning of experiments (zero time point, Ct(0)) as the reference value, computing the expression at later time points relative to time zero as: 2−(Ct(t)–Ct(0)), measured in relative units (RU) (Fig. S3A). After 17 h of incubation, the expression of candidate reference genes stabilized until the end of the experiments, i.e. until 96 h after cell dispersion (Fig. S3B). We also tested whether GnRH affects the expression of these candidate reference genes using female pituitary cells cultured overnight. The following morning, cells were washed and incubated in BSA-containing medium 199 supplemented with 10 nM GnRH for up to 8 h. Under these conditions the Ct values for Gapdh, Rpl19, and Rps18 did not change during incubation; Fig. S3C shows combined mean values from these experiments. 10 nM GnRH also had no effect on Gapdh expression during shorter and longer treatments (Fig. S3D).

Based on these findings, in further studies we used expression relative to time zero as described above to evaluate gene expression during the first 20 h of incubation after cell dispersion and termed such values as relative units (RU). For experiments done after 20 h of GnRH-free preincubation, such as those performed after overnight incubation, we used Gapdh and/or Rpl19 as reference genes for experiments and calculated expression relative to the reference gene as: 2^−(Ct(target gene) −Ct(reference gene)) × 100. To normalize values from several independent experiments, we also presented such data as fold change relative to time zero, with initial values shown as one.

Immunocytochemistry

For immunocytochemical analysis, 50,000/well freshly dispersed anterior pituitary cells were plated on poly-D-lysine coated 8-well multitest slides (MP Biomedicals, Aurora, OH) and cultured overnight. The following morning, cells were treated with 10 nM GnRH for 2, 4, 6 and 8 h. Cells were then washed twice with PBS and fixed with cold 4% formaldehyde solution (Thermo Scientific, Rockford, IL, USA) for 10 min at room temperature. After washing cells three times in PBS, cultures were bathed in medium with 1:200 rabbit anti-Egr1 15F7 (Cell Signaling Technology, Danvers, MA) or 1:100 mouse anti-Nr5a1 N1665 (ThermoFisher Scientific, Waltham, MA) antibodies overnight at 4 °C, then incubated with appropriate secondary antibody (Alexa Fluor 488 donkey anti-mouse or Alexa Fluor 488 goat anti-rabbit; Invitrogen, Carlsbad, CA; 1:1000) for 30 min at room temperature. For double immunostaining, pituitary cells were incubated with guinea pig anti-Lhb (1:250) (obtained from Dr. A. F. Parlow, National Institute of Diabetes and Digestive and Kidney Diseases, National Hormone and Peptide Program, Torrance, CA) overnight at 4 °C, followed by subsequent incubation with a suitable secondary antibody (Alexa Fluor 568 goat anti-guinea pig antibody; Invitrogen, Carlsbad, CA; 1:1000 dilution) for 30 min at room temperature. All antibodies were diluted in staining PBS solution containing 0.2% saponin and 0.5% BSA. Every step of the immunostaining protocol was followed by washing cells three times with PBS. Cells were mounted with Fluoromount-G, with 4′,6-diamidino-2-phenylindole, a fluorescent DNA stain (Invitrogen, Carlsbad, CA). To test the specificity of the reaction, control cells were treated in the same way with the exclusion of primary antibodies (data not shown). All images were acquired on an inverted confocal laser-scanning microscope (LSM 780; Carl Zeiss GmbH, Jena, Germany), using a 63x oil objective. Micrographs were sized, and their brightness and contrast levels adjusted in Fiji. Cells were counted on 5 tile-scan images (3 × 3).

Statistics

The numerical values are reported as the mean ± SEM from a representative set of at least three similar experiments, or normalized values from three to nine independent experiments per time point. KaleidaGraph (Synergy Software, Reading, Pennsylvania) was used for all calculation and graph presentation. Significant differences between means were determined by a single factor ANOVA or an ANOVA followed by the post hoc Student-Newman-Keuls test.

Results

Basal gonadotropin subunit and GnRH receptor gene expression patterns in vitro

Freshly dispersed rat anterior pituitary cells were plated and cultured in medium without GnRH for four days. Because of transient changes in Ct values for Gapdh and other candidate reference genes during the first 20 h after cell dispersion, we measured expression relative to expression at time zero (RU), as described in Methods: qRT-PCR analysis. Figure 1A shows bidirectional changes in Lhb expression after cell dispersion; an initial minor stimulatory effect followed by a minor sustained inhibition. In contrast, there was an initial deep inhibition in Fshb expression followed by a partial recovery of expression (B), and a progressive inhibition of Cga (C) and Gnrhr expression (D). These results show that expression of Lhb was relatively insensitive to loss of endogenous GnRH, in contrast to Fshb, Cga, and Gnrhr expression. A partial recovery of Fshb expression during prolonged culturing without changes of bath medium could indicate an autocrine/paracrine stimulatory effect.

Figure 1.

Figure 1

Open in a new tab

The expression patterns of gonadotropin subunit (A–C) and GnRH receptor (D) genes in rat anterior pituitary cells cultured in the absence of GnRH. Zero time points indicate the beginning of culturing after cell dispersion. Expression was measured relative to time zero in relative units (RU), as described in Methods: qRT-PCR analysis. In all panels, asterisks indicate significant difference vs. zero time point controls.

Gene-specific expression pattern during continuous GnRH receptor agonists application

In further experiments, anterior pituitary cells were cultured for 20 h after dispersion in the absence of GnRH, washed, and treated with 10 nM GnRH for 1, 2, 3, 4, 6, 8, 12, 18, and 24 h (Fig. 2A). Our control genes for this experiment, Gnrhr and Dmp1, responded as previously reported26,27; their expression was transiently stimulated, reaching a peak within 6 h of stimulation and followed by a gradual decay toward the basal level of gene expression (Fig. 2A). GnRH also stimulated Fshb expression transiently but peaking within 2–3 h of stimulation and followed by a rapid decay in gene expression below basal expression. After 6 h of incubation in the presence of GnRH, Fshb expression was abolished for the rest of the experiment. GnRH also stimulated Cga expression, but with a distinct temporal profile of expression; no changes in expression were observed during the first 8 h of culturing, followed by a slow increase that reached a peak in response after 18 h of stimulation. Finally, we did not observe consistent stimulatory effects of GnRH on Lhb expression during continuous application; instead observing only a small and transient inhibition of basal expression during the first 12 h of incubation. Similar patterns of responses were also observed in cultured pituitary cells from postpubertal male rats (data not shown). These data indicate the gonadotropin subunit gene-specific patterns of responses to continuous in vitro GnRH application.

Figure 2.

Figure 2

Open in a new tab

Time-course of GnRH receptor agonists on gonadotropin subunit genes, Gnrhr, and Dmp1 expression in cultured pituitary cells. (A) Effects of continuous GnRH application on gene expression. Note the transient nature of Fshb, Gnrhr, and Dmp1 expression, a slow and continuous upregulation in Cga expression, and a transient and minor inhibition of Lhb expression during GnRH treatment. Data shown are mean ± SEM values, normalized to the zero time point controls, from three to nine independent experiments per time point, each performed in quadruplicate. Asterisks indicate significant differences vs. zero time point. (B) A gene-specific patterns of expression in response to application of D-Ala6. Top panel indicates duration of first (blue) and second (red) 10 nM D-Ala6 application and washout periods (green). The data shown are mean ± SEM values from a representative experiment; when not visible, SEM values were within circles. Asterisks indicate a significant difference between pairs. In both panels, horizontal gray lines indicate basal gene expression and vertical dotted lines indicate times needed to reach the peak in expression. If not otherwise specified, in this and following figures experiments were performed with cells from postpubertal female rats. Immediately after dispersion, cells (1.5 million per well) were seeded in 24-well plates and cultured overnight in horse serum-containing GnRH-free medium. After 20 h incubation, medium was replaced with fresh 0.1% BSA-containing medium with GnRH or D-Ala6.

The progressive decay in Fshb, Gnrhr, and Dmp1 expression following the peak in response could reflect the rate of downregulation of stimulus-expression coupling in the presence of GnRH and/or the rate of GnRH degradation. To rule out the latter, in further experiments we substituted native GnRH with its degradation-resistant analog D-Ala6, which was applied once or twice during a 23 h period in static cultures of female pituitary cells, as shown on the top panel of Fig. 2B. If applied twice, the culture medium was changed between applications to provide a washout period of variable duration. The profiles of gene expression during the first 12 h of application of D-Ala6 were highly comparable to those seen in GnRH application, with bidirectional effects on Fshb expression, stimulatory effect on Cga expression, and a small downregulation of Lhb. The washout of D-Ala6 did not affect Fshb expression during 15 h of incubation, as indicated by the lack of return of expression to the pre-application basal level. Also, the subsequent application of agonist at different time points was unable to elevate expression of this gene. Lhb expression recovered with and without secondary application of D-Ala6. The ongoing rise in Cga expression observed after removal of D-Ala6 was amplified 34 ± 14% by secondary agonist application. Finally, there was significant recovery of Gnrhr expression during the secondary D-Ala6 application, with the amplitude of responses increasing with extension of washout duration. For example, at the end of the experiments, the response of Gnrhr was 32 ± 4.5% of that observed during the first D-Ala6 application. These experiments established that continuous GnRH in vitro downregulates Fshb expression, but not that of Cga, Lhb, and Gnrhr, below basal levels.

The lack of pronounced stimulation of Lhb expression during continuous 10 nM GnRH/D-Ala6 application, which is a pharmacological dose, prompted us to examine the full concentration dependence on GnRH of gene expression. To do this, static culture of pituitary cells were treated with 0.05, 0.1, 1, and 10 nM GnRH for 2, 4 and 6 h. The results of this concentration and time-course study, summarized in Fig. 3, confirmed the lack of a stimulatory effect and the presence of a minor inhibitory effect of GnRH on Lhb expression, with little effect of GnRH dose (Fig. 3A). In further parallelism with previous experiments, we observed a bidirectional effect of GnRH on Fshb expression, an early stimulatory and a sustained inhibitory effect (Fig. 3B). The time-course of GnRH-stimulated Fshb expression was comparable at all concentrations, with no effect of GnRH dose on the peak amplitude of responses, indicating maximal stimulatory action at picomolar GnRH concentrations. Conversely, downregulation of expression in the inhibitory phase was more pronounced with increasing GnRH concentration. The time course of GnRH-stimulated Gnrhr expression was also comparable at all GnRH concentrations, but the concentration dependence of this gene expression occurred later than the stimulatory component of the Fshb expression profile (Fig. 3C).

Figure 3.

Figure 3

Open in a new tab

Concentration- and time-dependent effects of GnRH on Lhb (A) Fshb (B) and Gnrhr (C) expression in cultured pituitary cells. GnRH was applied in 0.05–10 nM concentrations. Asterisks indicate significant differences vs. zero time point control (dotted lines).

In vitro expression of pituitary transcriptional factors controlling Lhb expression

To better understand the expression profile of Lhb expression, we examined the responses of Pitx1, Egr1, and Nr5a1 to dispersion, culturing, and GnRH application. As stated in the Introduction, these transcription factors contribute to stimulation of Lhb expression. Dispersion/culturing of pituitary cells had dramatic effects on expression of these genes. There was a rapid, progressive, and deep decrease in Egr1 expression, whereas Pitx1 and Nr5a1 expression was facilitated in the same experimental conditions (Fig. 4A). In contrast, continuous GnRH application had a rapid and profound inhibitory effect on Nr5a1 expression, did not alter Pitx1 expression, and induced a transient increase followed by a recovery to near baseline of Egr1 expression, followed by a sustained plateau response (Fig. 4B). The opposite effects of culturing of cells without and with GnRH on Egr1 and Nr5a1 expression clearly indicates that this agonist plays an important role in their expression, stimulatory for Egr1 and inhibitory for Nr5a1, whereas the expression of Pitx1 was insensitive to GnRH and so appears to be controlled by other hypothalamic and/or intrapituitary factor(s).

Figure 4.

Figure 4

Open in a new tab

The expression patterns of transcriptional factor genes controlling Lhb in anterior pituitary cells cultured in the absence and presence of GnRH. Changes in Pitx1, Egr1, and Nr5a1 expression in cells cultured for 96 h without GnRH (A) and in the presence of 10 nM GnRH, applied after 20 h culture in GnRH-free medium (B). Data points in A are mean ± SEM values from a representative experiment shown as relative units, and in B are normalized mean ± SEM values from four to nine experiments per time point, each done in quadruplicates. In all panels, asterisks indicate significant difference vs. zero time point controls.

In further studies, the expression of Egr1 and Nr5a1 proteins was evaluated in anterior pituitary cells cultured overnight in horse serum-containing medium, washed in the morning and treated with BSA-containing medium with or without 10 nM GnRH. Following treatment, cells were double-stained with Egr1 or Nr5a1 and Lhb antibodies as described in Methods: Immunocytochemistry. Prior to GnRH treatment, Egr1 immunoreactivity was detected only in 2% of Lhb-positive cells. Following 2 h GnRH treatment, there was a rapid rise in expression of Egr1 in Lhb-positive cells (37%). The number of Egr1-positive cells decreased with further duration of treatment, but stayed above basal expression (23, 12 and 9% following 4, 6 and 8 h treatment, respectively; Fig. 5A, left). In contrast, about 65% of Lhb-positive cells also expressed Nr5a1 in untreated cultures and there was a significant decay in the fraction of Nr5a1 positive gonadotrophs after 6 h (45%) and 8 h (7%) of treatment with GnRH (Fig. 5A, right). Representative images for immune staining of Egr1- and Nr5a1-positive gonadotrophs are shown in Fig. 5B,C, respectively. The lack of effect of continuous GnRH application on stimulation of Lhb expression may be explained by the opposing responses in Egr1 and Nr5a1 expression after cell dispersion and during GnRH treatment. Also, the minor downregulatory effect of GnRH on basal Lhb expression indicates that the majority of basal Lhb expression is not GnRH controlled, in contrast to Fshb expression.

Figure 5.

Figure 5

Open in a new tab

Immunofluorescence analysis of Egr1 and Nr5a1 expression in gonadotrophs. (A) Time course effect of GnRH treatment on Egr1 and Nr5a1 expression in Lhb-positive cells. (B,C) Representative images for immunocytostaining of Egr1- and Nr5a1-positive gonadotrophs. (B) Egr1 (green, left), Lhb (red, center), and their overlay (right) in untreated (top) and GnRH (10 nM/2 h) treated (bottom) pituitary cells. (C) Nr5a1 (green, left), Lhb (red, center), and their overlay (right) in untreated and GnRH (10 nM/8 h) treated (bottom) pituitary cells. Cell nuclei are stained with DAPI (blue). Arrows indicate Lhb-positive gonadotrophs that express either Egr1 or Nr5a1. Scale bars (applies to all images), 10 µm.

In vivo effects of buserelin and cetrorelix acetate on gonadotroph gene expression

Prepubertal female and male rats were injected with 5 µg of buserelin acetate, a GnRH receptor agonist, 100 µg of cetrorelix acetate, a GnRH receptor antagonist, or with vehicle (saline solution) intraperitoneally (Fig. 6). Animals were euthanized 0.5, 1, 1.5, and 2 h after injection (panel A), or 3, 6, and 9 h after injection (panels B-D), blood was collected for serum LH measurements and pituitary glands were removed for qRT-PCR analysis or LH tissue content measurements. We observed significant increases in Lhb expression only at one time point, 30 min after injection of buserelin acetate. Notice the lack of buserelin acetate effect on Lhb expression independent of the gene used for normalization of data, Gapdh (Fig. 6B) or Rpl19 (Fig. 6C). However, buserelin acetate injection resulted in significant and transient increases in Fshb, Gnrhr, and Dmp1 expression and a progressive increase in Cga expression. The timing for Cga, Gnrhr, and Dmp1 expression in vivo was comparable to in vitro expression, whereas Fshb expression reached peak response already 30 min after the treatment, followed by decay in response and beginning of recovery of response after 9 h treatment (Fig. 7). Parallelism in the stimulatory actions of GnRH receptor agonists on gonadotropin subunit genes and Gnrhr expression in vitro and in vivo further supports the gene-specific expression pattern during continuous receptor activation.

Figure 6.

Figure 6

Open in a new tab

Effects of in vivo injection of a GnRH receptor agonist and antagonist on Lhb expression. Experiments were performed with prepubertal female and male rats. (A–D) Effects of injection of buserelin acetate, a GnRH receptor agonist (5 µg/0.4 ml per animal), cetrorelix acetate, a GnRH receptor antagonist (100 µg/0.4 ml per animals,) or solvent (0.4 ml PBS) intraperitoneally. Animals were sacrificed 0.5, 1, 1.5 and 2 h after injection (A) or 3, 6 and 9 h after injection (B–D). Values were normalized vs. Gapdh (A,B,D) or Rpl19 (C).

Figure 7.

Figure 7

Open in a new tab

Effects of in vivo injection of a GnRH receptor agonist and antagonist on Fshb, Cga, Gnrhr, and Dmp1 expression. Experiments were performed with prepubertal female rats sacrificed 0.5, 1, 1.5 and 2 h after injection (A) or 3, 6 and 9 h after injection (B,C).

Independence of Lhb expression with respect to experimental conditions

It has been suggested that exposure of female pituitary cells to androgens is needed for establishing GnRH stimulus – transcriptional coupling36. To examine in vitro influence of androgens on Lhb expression, dispersed female pituitary cells were cultured overnight, washed and cultured for additional 24 h in the presence of 250 pg/ml dihydrotestosterone or 500 pg/ml testosterone, as previously described37. Cell were then washed and stimulated with 10 nM GnRH in the presence of androgens for 1–6 h. Figure S4 summarizes these investigations. Consistent with experiments without androgens (Fig. 2), GnRH also had a minor inhibitory effect on Lhb expression, but stimulated Gnrhr and Fshb expression during the first 6 h of exposure. The expression profiles for Gnrhr and Fshb were somewhat different in the presence of dihydrotestosterone and testosterone. Specifically, Gnrhr response was sigmoidal in the presence of dihydrotestosterone and linear in the presence of testosterone, and the duration of the upregulation phase of Fshb response was extended in the presence of testosterone (Fig. S4).

We also tested the validity of TaqMan probes and assay used for analysis. First, we used different TaqMan probes for Lhb and observed no difference in the expression pattern (data not shown). Second, we used static cultures of pituitary cells for 10 nM GnRH treatment (0 to 8 h) and SYBR-Green based assays with three different pairs of primers for evaluation of Lhb mRNA levels (Fig. S5A; Table S1). Consistent with the TaqMan assay, no stimulatory effect of GnRH on Lhb expression was observed by SYBR-Green assay. Finally, both TaqMan and SYBR-Green assays were used to evaluate in vivo Lhb expression after buserelin acetate and cetrorelix acetate injections; Fig. S5B summarizes results with TaqMan assay (left) and SYBR-Green assay (middle) and a significant correlation between values was obtained by the two assays (right), indicating the validity of both assays.

Characterization of the LH secretory actions of GnRH receptor agonists in vitro and in vivo

For secretory studies, 0.25 × 106 cells per well were cultured in 24-well plates overnight, washed in the morning and stimulated with 10 nM GnRH for 1–5 h. At the end of incubation, medium was collected, and LH was measured in incubation medium and cellular extracts. Figure 8 illustrates the time-courses of GnRH-induced LH release (A) and depletion of intracellular LH content (B); the time-dependent increase in LH release was accompanied by a progressive decrease in hormonal cell content. We also examined effects of cycloheximide, an inhibitor of eukaryotic protein synthesis, on 10 nM GnRH-induced LH release during 4 h incubation. This compound caused a profound reduction of GnRH-stimulated LH secretion (C), indicating that high basal Lhb and Cga transcription leads to de novo LH synthesis.

Figure 8.

Figure 8

Open in a new tab

GnRH receptor agonist-stimulated LH secretion in vitro and in vivo. (A,B) Time-courses of GnRH-induced LH release (A) and depletion of intracellular LH content (B). After overnight incubation, cells were stimulated with 10 nM GnRH for 1–5 h. At the end of incubation periods, medium (A) and cell lysates (B) were collected for LH measurements. (C) Concentration-dependent effect of cycloheximide, a eukaryote protein synthesis inhibitor, on 10 nM GnRH-induced LH release following 4 h incubation (normalized values). Asterisks indicate significant differences vs. untreated cells. (D,E) In vivo effects of buserelin acetate on serum (D) and intrapituitary (E) LH. Data shown are mean ± SEM, N = 5 per time point. Panels D and E shows combined data from short-term and long-term treatment with buserelin acetate and control females (compare Figs. 6 and 7).

In vivo injection of buserelin acetate also triggered LH secretion, as documented by measurements of serum LH concentration. There was a rapid increase in serum LH concentration, reaching a peak in secretion 90 min after injection, followed by a gradual decay (Fig. 8D). The spike phase temporally coincided with a rapid fall in pituitary LH tissue content (Fig. 8E). Nine hours after buserelin acetate treatment, pituitary LH tissue content was about 6% of that observed in controls. Taken together, these experiments indicate that during continuous treatment with high concentrations of GnRH receptor agonists there was no blockade of stimulus-secretion coupling and that basal Lhb expression and de novo LH synthesis are not sufficient to protect cells from depletion of the secretory pool.

Discussion

Here we examined the dependence of gonadotropin subunit and GnRH receptor gene expression patterns on GnRH in vitro and in vivo. After cell dispersion and culturing in GnRH-free medium, we observed a rapid decay in Fshb, Cga, and Gnrhr expression, but only a small decay in Lhb expression. We also showed significant changes in expression of reference genes commonly used for quantification of relative expression by qRT-PCR in the same conditions, but not in response to GnRH treatment, necessitating careful analysis in the first 20 h of primary culture. In further agreement with the role of GnRH receptors in Fshb, Cga, and Gnrhr expression, in vitro continuous treatments with both GnRH and its degradation-resistant analog D-Ala6 stimulated the expression of these genes, but with gene-specific kinetics. Fshb expression was bidirectional, with a rapid but transient upregulation, followed by a sustained downregulation in expression below the basal value observed in untreated cell cultures. Gnrhr expression was also transient, but with a delay in peak expression and without downregulation of expression below basal levels. Cga expression was only upregulated with about 6–8 h-delay in beginning of rise in expression. In contrast, we did not consistently observe upregulation of Lhb expression, and we recorded only a minor and transient inhibition from basal Lhb expression levels during the continuous presence of GnRH receptor agonists. In vivo injected buserelin acetate also transiently stimulated Fshb, Cga, and Gnrhr expression without obviously affecting Lhb expression. The expression of Dmp1, another gonadotroph-specific gene, was comparable to Gnrhr expression kinetics.

To our best knowledge, we present the first study of the effects of culturing cells in GnRH-free medium on the time course of expression of these genes, starting immediately after cell dispersion. We also believe this is the first detailed time-course analysis of the effects of continuous GnRH receptor agonist treatments on gonadotropin subunit gene expression in the rat model. Others have observed up-regulation in Fshb expression 1 h after GnRH application in rat pituitary fragments18 and downregulation in expression of this gene in rat pituitary cells cultured for 8 and 24 h in the presence of GnRH20 and 24 h after continuous exposure to GnRH in cultured mouse pituitary cells38. In contrast to our results, Shupnik reported stimulation in Lhb expression in static culture of rat pituitary fragments, and rapid effects (within 30 min) on Cga expression18. However, Weiss et al. reported no stimulatory effect of continuous GnRH treatment of cultured rat pituitary cells on Lhb expression 4, 8, and 24 h after continuous stimulation with GnRH20. The lack of effect of GnRH treatment on Lhb expression was also observed in pituitary cells from ovariectomized rats39. In contrast to gonadotropin subunit genes, previous experiments have well clarified that expression of Gnrhr decays during prolonged culturing in the absence and presence of GnRH26,40,41. GnRH treatment also elevates Dmp1 expression in vitro with similar kinetics and concentration dependence27,42. The same conclusion was reached in this study, which gave us confidence about the reproducibility of in vitro experiments and the validity of the novel conclusions for expression of gonadotropin subunit gene expression during continuous in vitro application.

Our experiments lead to at least four major conclusions: 1. The lack of ability of continuous GnRH treatment to modulate Lhb expression is consistent with the hypothesis that a pulsatile pattern of GnRH application may be a pre-requisite for detecting the upregulation in Lhb expression, which has been previously reported16–18. 2. Continuous GnRH treatment not only transiently stimulates Fshb expression, but also downregulates basal Fshb expression. FSH is known to be predominantly secreted by constitutive exocytosis. Consequently, the intrapituitary Fshb and circulating FSH levels are often highly correlated; i.e. Fshb expression is a good indicator of the secretory profile21. Thus, it is reasonable to conclude that blockade of Fshb expression by continuous GnRH treatment accounts for downregulation of FSH release in such treatments. 3. The difference in the peak response times for Fshb, Gnrhr/Dmp1, and Cga could provide a rationale for the observed differences in the GnRH pulse frequency in regulation of expression of these Fshb (low), Gnrhr (high), and Cga (high or continuous). This motivates further experiments to clarify the differences in the intracellular messengers and/or transcriptional factors controlling their expression. 4. Such divergent patterns of expression of gonadotropin subunit and GnRH receptor genes strongly argue against desensitization of GnRH receptors during continuous treatment. This is consistent with previous findings that the type I mammalian GnRH receptor does not desensitize, in contrast to other G protein-coupled receptors43 and non-mammalian forms of this receptor44. Our results also indicate that receptor signaling pathways are functional during continuous stimulation, accounting for a prolonged upregulation and downregulation of Cga and Fshb expression, respectively, and continuous LH secretion.

To understand why no stimulatory action of GnRH on Lhb expression was observed during continuous receptor activation, we studied the expression pattern of three transcription factors, Egr1, Nr5a1, and Pitx1, which have been suggested to be critical for controlling basal and/or GnRH receptor-regulated Lhb expression45. Egr1 null female mice are infertile and lack expression of Lhb24. This gene is induced rapidly by GnRH in immortalized gonadotrophs46 and cultured rat pituitary cells27,47. The action of Egr1 protein on Lhb transcription depends on Nr5a1 and Pitx125,48, and such a pattern of regulation is largely conserved among mammals49. Consistent with this model, it has been suggested that GnRH stimulates Nr5a1 expression50. However, others reported inhibitory effects of GnRH on expression of this gene51. In our preparation, Egr1 and Pitx1 were expressed in all subpopulations of pituitary cells, including gonadotrophs, whereas Nr5a1 was detected only in gonadotrophs35. Here we showed that Egr1 expression rapidly declined and that protein expression was observed only in 2% of cells after 20 h incubation in GnRH-free medium. The loss of Egr1 proteins in cultured gonadotrophs was not accompanied by dramatic changes in basal Lhb expression. The subsequent addition of GnRH only partially restored the expression of this gene and protein. Furthermore, Nr5a1 gene and protein expression was downregulated during continuous GnRH application. Thus, it is reasonable to speculate that basal Lhb expression is independent of the presence of Egr1 and that pulsatile GnRH application is required for the proper expression of Egr1/Nr5a1 and their coupling to Lhb expression.

The presence of high basal Lhb expression combined with the lack of sustained downregulation in Lhb expression during continuous GnRH application raised a question concerning the mechanism accounting for downregulation of LH secretion. It is well established that LH is predominantly secreted by regulated exocytosis22, and that GnRH is a very potent secretagogue1, which led us to examine the status of LH secretion under conditions used for studies on Lhb expression. We observed downregulation of LH secretion in vitro during sustained application of high concentrations of GnRH despite sustained Lhb expression. We also observed almost complete depletion of the LH secretory pool in gonadotrophs in vivo after injection of buserelin acetate despite elevated Lhb expression. These results indicate that downregulation of secretion occurs downstream of Lhb expression, probably at the level of de novo LH synthesis and/or maintenance of the secretory pool. It has already been suggested that translational control of gene expression could provide a rationale for some aspects of GnRH receptor signaling and secretion that could not be explained by changes at the level of transcription52. In that respect, it is illustrative that cycloheximide, an inhibitor of translational elongation, has a profound and time-dependent effects on LH release. These findings raise the possibility that pulsatile GnRH provides a mechanism for sustained LH release by allowing sufficient time for de novo LH synthesis to replenish the LH secretory pool. Further experiments are needed to clarify the status of LH secretory pool during sustained application of variable GnRH concentrations, and the kinetics of repletion of the secretory pool after removal of GnRH receptor agonists.

Supplementary information

Supplementary Information (849.6KB, docx)

Acknowledgements

We would like to thank Marek Kucka and Aloa Lamarca Dams for help with some experiments and Djurdjica Coss for helpful suggestions. This work was supported by funding from the NIH Intramural Research Program of the NICHD (HD000195-25) and NIDDK DK013028-12), and the Ministry of Education, Science and Technological Development of the Republic of Serbia (Grant III 41014). Confocal imaging was performed at the NICHD Microscopy and Imaging Core of the NIH, with the kind assistance of Vincent Schram and Lynne Holtzclaw.

Author contributions

S.S.: conceptualization; M.J., R.P., K.S., D.A. and I.B.: experimental work; M.J., R.P., P.F., K.S. and S.S.: data analysis and figure preparation; S.S.: writing – original draft; M.J., R.P., P.F., A.S., K.S., I.B. and S.S.: writing – review and editing; A.S. and S.S. supervision and funding acquisition.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Marija M. Janjic and Rafael M. Prévide.

Supplementary information

is available for this paper at 10.1038/s41598-019-56480-1.

References

  • 1.McArdle, C. A. & Roberson, M. S. Gonadotropes and gonadotropin-releasing hormone signaling. Fourth Edition edn, Vol. 1 335–397 (Elsevier, 2015).
  • 2.Coss D. Regulation of reproduction via tight control of gonadotropin hormone levels. Mol Cell Endocrinol. 2018;463:116–130. doi: 10.1016/j.mce.2017.03.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Herbison AE. The Gonadotropin-Releasing Hormone Pulse Generator. Endocrinology. 2018;159:3723–3736. doi: 10.1210/en.2018-00653. [DOI] [PubMed] [Google Scholar]
  • 4.Stojilkovic SS, Reinhart J, Catt KJ. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr Rev. 1994;15:462–499. doi: 10.1210/edrv-15-4-462. [DOI] [PubMed] [Google Scholar]
  • 5.Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978;202:631–633. doi: 10.1126/science.100883. [DOI] [PubMed] [Google Scholar]
  • 6.Wildt L, et al. Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology. 1981;109:376–385. doi: 10.1210/endo-109-2-376. [DOI] [PubMed] [Google Scholar]
  • 7.Maggi R, et al. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Hum Reprod Update. 2016;22:358–381. doi: 10.1093/humupd/dmv059. [DOI] [PubMed] [Google Scholar]
  • 8.Crowley WF, Jr., McArthur JW. Simulation of the normal menstrual cycle in Kallman’s syndrome by pulsatile administration of luteinizing hormone-releasing hormone (LHRH) J Clin Endocrinol Metab. 1980;51:173–175. doi: 10.1210/jcem-51-1-173. [DOI] [PubMed] [Google Scholar]
  • 9.Leyendecker G, Struve T, Plotz EJ. Induction of ovulation with chronic intermittent (pulsatile) administration of LH-RH in women with hypothalamic and hyperprolactinemic amenorrhea. Arch Gynecol. 1980;229:177–190. doi: 10.1007/BF02108310. [DOI] [PubMed] [Google Scholar]
  • 10.Zheng J, et al. Pulsatile GnRH Therapy May Restore Hypothalamus-Pituitary-Testis Axis Function in Patients With Congenital Combined Pituitary Hormone Deficiency: A Prospective, Self-Controlled Trial. J Clin Endocrinol Metab. 2017;102:2291–2300. doi: 10.1210/jc.2016-3990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kashyap S, Parker K, Cedars MI, Rosenwaks Z. Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose. Semin Reprod Med. 2010;28:475–485. doi: 10.1055/s-0030-1265674. [DOI] [PubMed] [Google Scholar]
  • 12.Ying Y, Yang T, Zhang H, Liu C, Zhao J. Prolonged pituitary down-regulation with full-dose of gonadotropin-releasing hormone agonist in different menstrual cycles: a retrospective cohort study. PeerJ. 2019;7:e6837. doi: 10.7717/peerj.6837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lambertini M, Horicks F, Del Mastro L, Partridge AH, Demeestere I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. Cancer Treat Rev. 2019;72:65–77. doi: 10.1016/j.ctrv.2018.11.006. [DOI] [PubMed] [Google Scholar]
  • 14.Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab. 2013;98:2198–2207. doi: 10.1210/jc.2013-1024. [DOI] [PubMed] [Google Scholar]
  • 15.Lainas TG, et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT) Hum Reprod. 2010;25:683–689. doi: 10.1093/humrep/dep436. [DOI] [PubMed] [Google Scholar]
  • 16.Haisenleder DJ, Dalkin AC, Ortolano GA, Marshall JC, Shupnik MA. A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology. 1991;128:509–517. doi: 10.1210/endo-128-1-509. [DOI] [PubMed] [Google Scholar]
  • 17.Kaiser UB, Jakubowiak A, Steinberger A, Chin WW. Differential effects of gonadotropin-releasing hormone (GnRH) pulse frequency on gonadotropin subunit and GnRH receptor messenger ribonucleic acid levels in vitro. Endocrinology. 1997;138:1224–1231. doi: 10.1210/endo.138.3.4968. [DOI] [PubMed] [Google Scholar]
  • 18.Shupnik MA. Effects of gonadotropin-releasing hormone on rat gonadotropin gene transcription in vitro: requirement for pulsatile administration for luteinizing hormone-beta gene stimulation. Mol Endocrinol. 1990;4:1444–1450. doi: 10.1210/mend-4-10-1444. [DOI] [PubMed] [Google Scholar]
  • 19.Burger LL, Haisenleder DJ, Aylor KW, Marshall JC. Regulation of intracellular signaling cascades by GNRH pulse frequency in the rat pituitary: roles for CaMK II, ERK, and JNK activation. Biol Reprod. 2008;79:947–953. doi: 10.1095/biolreprod.108.070987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Weiss J, Jameson JL, Burrin JM, Crowley WF., Jr. Divergent responses of gonadotropin subunit messenger RNAs to continuous versus pulsatile gonadotropin-releasing hormone in vitro. Mol Endocrinol. 1990;4:557–564. doi: 10.1210/mend-4-4-557. [DOI] [PubMed] [Google Scholar]
  • 21.Farnworth PG. Gonadotrophin secretion revisited. How many ways can FSH leave a gonadotroph? J Endocrinol. 1995;145:387–395. doi: 10.1677/joe.0.1450387. [DOI] [PubMed] [Google Scholar]
  • 22.Tse FW, Tse A, Hille B, Horstmann H, Almers W. Local Ca2+ release from internal stores controls exocytosis in pituitary gonadotrophs. Neuron. 1997;18:121–132. doi: 10.1016/S0896-6273(01)80051-9. [DOI] [PubMed] [Google Scholar]
  • 23.Le Drean Y, Liu D, Xiong F, Hew CL. Presence of distinct cis-acting elements on gonadotropin gene promoters in diverse species dictates the selective recruitment of different transcription factors by steroidogenic factor-1. Mol Cell Endocrinol. 1997;135:31–40. doi: 10.1016/S0303-7207(97)00184-6. [DOI] [PubMed] [Google Scholar]
  • 24.Lee SL, et al. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1) Science. 1996;273:1219–1221. doi: 10.1126/science.273.5279.1219. [DOI] [PubMed] [Google Scholar]
  • 25.Tremblay JJ, Drouin J. Egr-1 is a downstream effector of GnRH and synergizes by direct interaction with Ptx1 and SF-1 to enhance luteinizing hormone beta gene transcription. Mol Cell Biol. 1999;19:2567–2576. doi: 10.1128/MCB.19.4.2567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bjelobaba I, et al. The relationship between basal and regulated Gnrhr expression in rodent pituitary gonadotrophs. Mol Cell Endocrinol. 2016;437:302–311. doi: 10.1016/j.mce.2016.08.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kucka M, Bjelobaba I, Clokie SJ, Klein DC, Stojilkovic SS. Female-specific induction of rat pituitary dentin matrix protein-1 by GnRH. Mol Endocrinol. 2013;27:1840–1855. doi: 10.1210/me.2013-1068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bargi-Souza P, et al. Loss of basal and TRH-stimulated Tshb expression in dispersed pituitary cells. Endocrinology. 2015;156:242–254. doi: 10.1210/en.2014-1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kozera B, Rapacz M. Reference genes in real-time PCR. J Appl Genet. 2013;54:391–406. doi: 10.1007/s13353-013-0173-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Lisowski P, Pierzchala M, Goscik J, Pareek CS, Zwierzchowski L. Evaluation of reference genes for studies of gene expression in the bovine liver, kidney, pituitary, and thyroid. J Appl Genet. 2008;49:367–372. doi: 10.1007/BF03195635. [DOI] [PubMed] [Google Scholar]
  • 31.van Rijn SJ, et al. Expression stability of reference genes for quantitative RT-PCR of healthy and diseased pituitary tissue samples varies between humans, mice, and dogs. Mol Neurobiol. 2014;49:893–899. doi: 10.1007/s12035-013-8567-7. [DOI] [PubMed] [Google Scholar]
  • 32.Zinzow-Kramer WM, Horton BM, Maney DL. Evaluation of reference genes for quantitative real-time PCR in the brain, pituitary, and gonads of songbirds. Horm Behav. 2014;66:267–275. doi: 10.1016/j.yhbeh.2014.04.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Bujko M, Rusetska N, Mikula M. Validating candidate reference genes for qRT-PCR-based gene expression analysis in nonfunctioning pituitary adenomas. Pituitary. 2016;19:110–112. doi: 10.1007/s11102-015-0656-3. [DOI] [PubMed] [Google Scholar]
  • 34.Normann KR, et al. Selection and validation of reliable reference genes for RT-qPCR analysis in a large cohort of pituitary adenomas. Mol Cell Endocrinol. 2016;437:183–189. doi: 10.1016/j.mce.2016.08.030. [DOI] [PubMed] [Google Scholar]
  • 35.Fletcher, P. A. et al. Cell Type- and Sex-Dependent Transcriptome Profiles of Rat Anterior Pituitary Cells. Front Endocrinol10, 10.3389/fendo.2019.00623 (2019). [DOI] [PMC free article] [PubMed]
  • 36.Yasin M, Dalkin AC, Haisenleder DJ, Marshall JC. Testosterone is required for gonadotropin-releasing hormone stimulation of luteinizing hormone-beta messenger ribonucleic acid expression in female rats. Endocrinology. 1996;137:1265–1271. doi: 10.1210/endo.137.4.8625898. [DOI] [PubMed] [Google Scholar]
  • 37.Haisenleder D. J., Burger L. L., Walsh H. E., Stevens J., Aylor K. W., Shupnik M. A., Marshall J. C. Pulsatile Gonadotropin-Releasing Hormone Stimulation of Gonadotropin Subunit Transcription in Rat Pituitaries: Evidence for the Involvement of Jun N-Terminal Kinase But Not p38. Endocrinology. 2008;149(1):139–145. doi: 10.1210/en.2007-1113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Yeh DM, Coss D. PACAP induces FSHbeta gene expression via EPAC. Mol Cell Endocrinol. 2019;492:110438. doi: 10.1016/j.mce.2019.04.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Salton SR, Blum M, Jonassen JA, Clayton RN, Roberts JL. Stimulation of pituitary luteinizing hormone secretion by gonadotropin-releasing hormone is not coupled to beta-luteinizing hormone gene transcription. Mol Endocrinol. 1988;2:1033–1042. doi: 10.1210/mend-2-11-1033. [DOI] [PubMed] [Google Scholar]
  • 40.Cheon M, Park D, Kim K, Park SD, Ryu K. Homologous upregulation of GnRH receptor mRNA by continuous GnRH in cultured rat pituitary cells. Endocrine. 1999;11:49–55. doi: 10.1385/ENDO:11:1:49. [DOI] [PubMed] [Google Scholar]
  • 41.White BR, Duval DL, Mulvaney JM, Roberson MS, Clay CM. Homologous regulation of the gonadotropin-releasing hormone receptor gene is partially mediated by protein kinase C activation of an activator protein-1 element. Mol Endocrinol. 1999;13:566–577. doi: 10.1210/mend.13.4.0262. [DOI] [PubMed] [Google Scholar]
  • 42.Bjelobaba I, et al. Distinct Expression Patterns of Osteopontin and Dentin Matrix Protein 1 Genes in Pituitary Gonadotrophs. Front Endocrinol (Lausanne) 2019;10:248. doi: 10.3389/fendo.2019.00248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004;27:107–144. doi: 10.1146/annurev.neuro.27.070203.144206. [DOI] [PubMed] [Google Scholar]
  • 44.Hislop JN, et al. Desensitization and internalization of human and xenopus gonadotropin-releasing hormone receptors expressed in alphaT4 pituitary cells using recombinant adenovirus. Endocrinology. 2000;141:4564–4575. doi: 10.1210/endo.141.12.7813. [DOI] [PubMed] [Google Scholar]
  • 45.Halvorson LM. Transcriptional regulation of the LH beta gene by gonadotropin-releasing hormone and the protein kinase C system. Vitam Horm. 2000;60:195–227. doi: 10.1016/S0083-6729(00)60020-1. [DOI] [PubMed] [Google Scholar]
  • 46.Reddy GR, Xie C, Lindaman LL, Coss D. GnRH increases c-Fos half-life contributing to higher FSHbeta induction. Mol Endocrinol. 2013;27:253–265. doi: 10.1210/me.2012-1168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Burger LL, Haisenleder DJ, Aylor KW, Marshall JC. Regulation of Lhb and Egr1 gene expression by GNRH pulses in rat pituitaries is both c-Jun N-terminal kinase (JNK)- and extracellular signal-regulated kinase (ERK)-dependent. Biol Reprod. 2009;81:1206–1215. doi: 10.1095/biolreprod.109.079426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Dorn C, Ou Q, Svaren J, Crawford PA, Sadovsky Y. Activation of luteinizing hormone beta gene by gonadotropin-releasing hormone requires the synergy of early growth response-1 and steroidogenic factor-1. J Biol Chem. 1999;274:13870–13876. doi: 10.1074/jbc.274.20.13870. [DOI] [PubMed] [Google Scholar]
  • 49.Fortin J, Lamba P, Wang Y, Bernard DJ. Conservation of mechanisms mediating gonadotrophin-releasing hormone 1 stimulation of human luteinizing hormone beta subunit transcription. Mol Hum Reprod. 2009;15:77–87. doi: 10.1093/molehr/gan079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Zielinska-Gorska, M. et al. Gonadotropin-releasing hormone and kisseptin-10 regulate nuclear receptor subfamily 5 group a member 1/catenin beta 1/nuclear receptor subfamily 0 group B member 1 activity in female rat anterior pituitary gland. J Physiol Pharmacol69, 10.26402/jpp.2018.3.14 (2018). [DOI] [PubMed]
  • 51.Zheng W, Jimenez-Linan M, Rubin BS, Halvorson LM. Anterior pituitary gene expression with reproductive aging in the female rat. Biol Reprod. 2007;76:1091–1102. doi: 10.1095/biolreprod.106.057877. [DOI] [PubMed] [Google Scholar]
  • 52.Kim T, Do MH, Lawson MA. Translational control of gene expression in the gonadotrope. Mol Cell Endocrinol. 2014;385:78–87. doi: 10.1016/j.mce.2013.09.007. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information (849.6KB, docx)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES